期刊文献+

胃饥饿素与胃癌手术后化疗相关性恶心呕吐的关系研究

Study on the relationship between ghrelin and chemotherapy-induced nausea and vomiting after operation for gastric cancer
下载PDF
导出
摘要 目的探讨胃饥饿素(Ghrelin)水平的变化与胃癌手术后化疗相关性恶心呕吐(CINV)发生的关系。方法选择确诊并行根治性胃癌切除术患者90例,手术后第3周进行化学治疗2周(1个疗程),均采用FOLFOX4化疗方案。将化疗后出现恶心呕吐的患者设定为CINV组(n=61),未出现恶心呕吐的患者设定为非CINV组(n=29)。全组患者分别于化疗前1 d及化疗开始后第2、4、7、14 d采用ELISA法检测血浆Ghrelin表达水平,比较并分析两组化疗前后Ghrelin水平变化和化疗相关性恶心呕吐(CINV)发生的关系。结果CINV组患者血浆Ghrelin表达水平在化疗后第2、4 d较化疗前明显下降,差异具有统计学意义(p<0.01);而非CINV组血浆Ghrelin表达水平在化疗后第2、4、7 d较化疗前无明显变化,差异无统计学意义(P>0.05)。结论血浆中Ghrelin可能具有抑制胃癌手术后发生CINV的作用,提示胃癌手术后使用Ghrelin激动剂或类似药物可望对CINV的发生具有防治作用。 Objective:To investigate the relationship between the change of Ghrelin level and the occurrence of chemotherapy-induced nausea and vomiting(CINV)after surgery for gastric cancer.Methods:90 patients with concurrent radical gastrectomy for gastric cancer were selected and treated with FOLFOX4 chemotherapy for 2 weeks(1 cycle)at 3 weeks after surgery.Patients with nausea and vomiting after chemotherapy were set as CINV group(n=61),and patients without nausea and vomiting were set as non-CINV group(n=29).Plasma Ghrelin levels were detected by ELISA in the whole group 1 day before chemotherapy and 2,4,7 and 14 days after chemotherapy.The relationship between Ghrelin levels before and after chemotherapy and occurrence of chemotherapy-induced nausea and vomiting(CINV)in the two groups was compared and analyzed.Results:Plasma Ghrelin expression level in CINV group was significantly lower on day 2 and 4 after chemotherapy than before chemotherapy,and the difference was statistically significant(P<0.01).However,the plasma Ghrelin expression level of the non-CINV group showed no significant change on days 2,4 and 7 after chemotherapy compared with that before chemotherapy,and the difference was not statistically significant(P>0.05).Conclusion:Ghrelin in plasma may inhibit the occurrence of CINV after gastric cancer surgery,suggesting that the use of Ghrelin agonists or similar drugs is expected to have a preventive and therapeutic effect on the occurrence of CINV after surgery for gastric cancer.
作者 王金磊 WANG Jin-lei(Dept.of Surgery,Taian City Traffic Hospital,Tai an 271000,China)
出处 《泰山医学院学报》 CAS 2020年第8期583-585,共3页 Journal of Taishan Medical College
关键词 胃饥饿素 胃癌 手术治疗 化疗相关性恶心呕吐 ghrelin gastric cancer surgical treatment chemotherapy-induced nausea and vomiting
  • 相关文献

参考文献11

二级参考文献106

  • 1张亚萍,石德红,张宽学,罗金燕.糖尿病大鼠胃肠功能紊乱时β_2-肾上腺素能受体与5-羟色胺受体表达的变化[J].中华糖尿病杂志(1006-6187),2004,12(4):297-299. 被引量:8
  • 2陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量:48
  • 3彭学清,曾玲,周述香,刘义钊,张勇.我国健康受试者体内帕洛诺司琼的药物动力学研究[J].中南药学,2007,5(4):322-325. 被引量:4
  • 4Geling O, Eichler HG. Should 5-hydmxytrypanfine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oneol, 2005, 23 : 1289-1294.
  • 5Coates A, Abraham S, Kaye SB, et al. On the receiving end-- patient perception of the side-effects of cancer chemotherapy. EurJ Clin Oneol, 1984, 19:203-208.
  • 6Oge A, Alki~ N, Oge O, et al. Comparison of granisetron, ondansetron and tmpisetron for control of vomiting and nausea induced by cisplatin. J Chemother, 2000, 12:105-108.
  • 7Aapro MS, Grunberg SM, Manikhas GM, et al. A phase 111, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 2006, 17 : 1441-1449.
  • 8Maemondo M, Masuda N, Sekine I, et al. A phase ]] study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol, 2009, 20 : 1860-1866.
  • 9Yu Z, Liu W, Wang L, et al. ~Ihe efficacy and safety of palonosetmn compared with granisetron in preventing highly emetogenie chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer, 2009, 17: 99- 102.
  • 10Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. In~oroved prevention of n~derately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase 1~, single-dose trial versus dolasetron. Cancer, 2003, 98:2473-2482.

共引文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部